Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction

British Journal of Cancer

Volumn 88, Issue 9, 2003, Pages 1445-1452

  Wagenaar Miller, R A ^a   Hanley, G ^b   Shattuck Brandt, R ^a,b   DuBois, R N ^a,b   Bell, R L ^c   Matrisian, L M ^a   Morgan, D W ^d  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c ABBOTT LABORATORIES   (United States)

^d TAP PHARMACEUTICAL PRODUCTS INC   (United States)

Author keywords

Colon cancer; Cyclooxygenase 2; Matrix metalloproteinase; Multiple intestinal neoplasia

Indexed keywords

A 177430; A 285969; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER PREVENTION; CARCINOGENESIS; CELL PROLIFERATION; COLON CANCER; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG TOLERABILITY; ENZYME INHIBITION; FAMILIAL CANCER; GENE EXPRESSION; INTESTINE POLYP; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ADENOMA; ANIMALS; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; ENZYME INHIBITORS; INTESTINAL NEOPLASMS; ISOENZYMES; MATRIX METALLOPROTEINASES; MICE; MICE, INBRED C57BL; PEPTIDES, CYCLIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EID: 0038751784     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600867     Document Type: Article

References (62)

1. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ, Patierno SR (2000) Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 60: 4629-4637
2. Ballif BA, Mincek NV, Barratt JT, Wilson ML, Simmons DL (1996) Interaction of cyclooxygenases with an apoptosis and immunity associated protein. Proc Natl Acad Sci USA 93: 5544-5549
3. Beazer-Barclay Y, Levy DB, Moser AR, Dove WF, Hamilton SR, Vogelstein B, Kinzler KW (1996) Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis 17; 1757-1760
4. Berenbaum MC (1977) Synergy, additivism and antagonism in immunosuppression. A critical review. Clin Exp Immunot 28: 1-18
5. Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L, Martin-Sanz P (2001) Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology 33: 860-867
6. Castano E, Bartrons R, Gil J (2000) Inhibition of cyclooxygenase-2 decreases DNA synthesis induced by platelet-derived growth factor in Swiss 3T3 fibroblasts. J Pharmacol Exp Ther 293: 509-513
7. Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95: 681-686
8. Coussens LM, Fingleton B, Matrisian LM (2002) Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295: 2387-2392
9. DuBois RN, Shao J, Tsujii M, Sheng H, Beauchamp RD (1996) G1 delay in cells overexpressing prostaglandin endoperoxide synthase-2. Cancer Res 56: 733-737
10. Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, DuBois RN (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107: 1183-1188
11. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161-174
12. Fearon ER, Vogelstein B (1990) A genetic model for colorectal tumorigenesis. Cell 61: 759-767
13. Fielding J, Scholefield J, Stuart R, Hawkins R, McCulloch P, Maughan T, Seymour M, Van Cutsem E, Thorlacius-Ussing O, Hovnanian A. A randomized double-blind placebo-controlled study of marimistat in patients with inoperable gastric adenocarcinoma (2000). Proc Am Soc Clin Oncol 19: 240A
14. Fosslien E (2000) Molecular pathology of cyclooxygenase-2 in neoplasia. Ann Clin Lab Sci 30: 3-21
15. Gann PH, Manson JE, Glynn RJ, Buring JE, Hennekens CH (1993) Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst 85: 1220-1224
16. Gilroy DW, Saunders MA, Sansores-Garcia L, Matijevic-Aleksic N, Wu KK (2001) Cell cycle-dependent expression of cyclooxygenase-2 in human fibroblasts. FASEB J 15: 288-290
17. Goss KJ, Brown PD, Matrisian LM (1998) Differing effects of endogenous and synthetic inhibitors of metalloproteinases on intestinal tumorigenesis. Int J Cancer 78: 629-635
18. Hawk E, Lubet R, Limburg P (1999) Chemoprevention in hereditary colorectal cancer syndromes. Cancer 86: 2551-2563
19. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS (2000) The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem 275: 11397-11403
20. Ito A, Nose T, Takahashi S, Mori Y (1995) Cyclooxygenase inhibitors augment the production of pro-matrix metalloproteinase 9 (progelatinase B) in rabbit articular chondrocytes. FEBS Lett 360: 75-79
21. Jacoby RF, Marshall DJ, Newton MA, Novakovic K, Tutsch K, Cole CE, Lubet RA, Kelloff GJ, Verma A, Moser AR, Dove WF (1996) Chemoprevention of spontaneous intestinal adenomas in the Apc Min mouse model by the nonsteroidal anti-inflammatory drug Piroxicam. Cancer Res 56: 710-714
22. Jiang MC, Liao CF, Lee PH (2001) Aspirin inhibits matrix metalloproteinase-2 activity, increases E- cadherin production, and inhibits in vitro invasion of tumor cells. Biochem Biophys Res Commun 282: 671-677
23. Jiang Y, Goldberg ID, Shi YE (2002) Complex roles of tissue inhibitors of metalloproteinases in cancer. Oncogene 21: 2245-2252
24. Jones MK, Wang H, Peskar BM, Levin E, Itani RM, Sarfeh IJ, Tarnawski AS (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 5: 1418-1423
25. Kargman SL, O'Neill GP, Vickers PJ, Evans JF, Mancini JA, Jothy S (1995) Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 55: 2556-2559
26. Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer. Cell 87: 159-170
27. Kujubu DA, Fletcher BS, Varnum BC, Lim RW, Herschman HR (1991) TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 266: 12866-12872
28. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL (2002) Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res 62: 625-631
29. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T (2001) Overexpression of cydooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem 276: 18563-18569
30. Liu LT, Chang HC, Chiang LC, Hung WC (2002) Induction of RECK by nonsteroidal anti-inflammatory drugs in lung cancer cells. Oncogene 21: 8347-8350
31. Marnett LJ (1995) Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prey Med 24: 103-106
32. Marnett LJ, DuBois RN (2002) COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol 42: 55-80
33. McDonnell S, Navre M, Coffey RJ, Matrisian LM (1991) Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinomas. Mol Carcinog 4: 527-533
34. McLaren J, Taylor DJ, Bell SC (2000) Prostaglandin E(2)-dependent production of latent matrix metalloproteinase-9 in cultures of human fetal membranes. Mol Hum Reprod 6: 1033-1040
35. Moser AR, Pitot HC, Dove WF (1990) A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 247: 322-324
36. Nelson AR, Fingleton B, Rothenberg ML, Matrisian LM (2000) Matrix metalloproteinases: biologic activity and clinical implications. J Clin Oncol 18: 1135-1149
37. Neri A, Goggin B, Kolis S (1998) Pharmacokinetics and efficacy of a novel matrix metalloproteinase inhibitor, AG3340, in single agent and combination therapy against B16-F10 melanoma tumors developing in the lung after IV-tail vein implantation in C57BL/6 mice. Proc Am Assoc Cancer Res 39: 302
38. Newell KJ, Witty JP, Rodgers WH, Matrisian LM (1994) Expression and localization of matrix-degrading metailoproteinases during colorectal tumorigenesis. Mol Carcinog 10: 199-206
39. O'Banion MK, Sadowski HB, Winn V, Young DA (1991) A serum- and glucocorticoid-regulated 4-kilobase mRNA encodes a cyclooxygenase-related protein. J Biol Chem 266: 23261-23267
40. Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM (1996) Suppression of intestinal polyposis in APC delta 716 knockout mice by inhbition of cyclooxygenase 2 (COX-2). Cell 87: 803-809
41. Pan MR, Chuang LY, Hung WC (2001) Non-steroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett 508: 365-368
42. Pan MR, Hung WC (2002) Nonsteroidal anti-inflammatory drugs inhibit matrix metalloproteinase-2 via suppression of the ERK/Sp1-mediated transcription. J Biol Chem 277: 32775-32780
43. Prescott SM, Fitzpatrick FA (2000) Cyclooxygenase-2 and carcinogenesis. Biochim Biophys Acta 1470: M69-M78
44. Rabbani SA, Harakidas P, Guo Y, Steinman D, Davidsen SK, Morgan DW (2000) Synthetic inhibitor of matrix metalloproteases decreases tumor growth and metastases in a syngeneic model of rat prostate cancer in vivo. Int J Cancer 87: 276-282
45. Reddy BS (1987) Dietary fiber and colon cancer: animal model studies. Prey Med 16: 559-565
46. Sano H, Kawahito Y, Wilder RL, Hashiramoto A, Mukai S, Asai K, Kimura S, Kato H, Kondo M, Hla T (1995) Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res 55: 3785-3789
47. Shattuck-Brandt RL, Lamps LW, Heppner Goss KJ, DuBois RN, Matrisian LM (1999) Matrilysin and cyclooxygenase-2 are differentially expressed in intestinal and colorectal neoplasms. Mol Carcinog 24: 177-187
48. Sheng H, Shao J, Kirldand SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN (1997) Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 99: 2254-2259
49. Sheppard GS, Florjancic AS, Giesler JR, Xu L, Guo Y, Davidsen SK, Marcotte PA, Elmore I, Albert DH, Magoc TJ, Bouska JJ, Goodfellow CL, Morgan DW, Summers JB (1998) Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors. Bioorg Med Chem Lett 8: 3251-3256
50. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM (2002) Cyclooxygenase-2 expression in fibroblasts and endothelial ceils of intestinal polyps. Cancer Res 62: 6846-6849
51. Stetler-Stevenson WG (1999) Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241
52. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, Gould KA, Dove WF (1992) Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 256: 668-670
53. Takahashi S, Inoue T, Higaki M, Mizushima Y (1997) Cyclooxygenase inhibitors enhance the production of tissue inhibitor-1 of metalloproteinases (TIMP-1) and pro-matrix metalloproteinase 1 (proMMP-1) in human rheumatoid synovial fibroblasts. Inflamm Res 46: 320-323
54. Takahashi Y, Kawahara F, Noguchi M, Miwa K, Sato H, Seiki M, Inoue H, Tanabe T, Yoshimoto T (1999) Activation of matrix metalloproteinase-2 in human breast cancer ceils overexpressing cydooxygenase-1 or -2. FEBS Lett 460: 145-148
55. Takeuchi N, Ichikawa T, Momiyama N, Hasegawa S, Nagashima Y, Miyazaki K, Koshikawa N, Mitsuhashi M, Shimada H (1997) Matrilysin gene expression in sporadic and familial colorectal adenomas. Mol Carcinog 19: 225-229
56. Thun MJ, Henley SJ, Patrono C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266
57. Torrance CJ, Jackson PE, Montgomery E, Kinzler KW, Vogelstein B, Wissner A, Nunes M, Frost P, Discafani CM (2000) Combinatorial chemoprevention of intestinal neoplasia. Nat Med 6: 1024-1028
58. Wargovich MJ, Chen CD, Harris C, Yang E, Velasco M (1995) Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 60: 515-519
59. Whitehead RH, Joseph JL (1994) Derivation of conditionally immortalized cell lines containing the Min mutation from the normal colonic mucosa and other tissues of an 'Immortomouse'/Min hybrid. Epithelial Cell Biol 3: 119-125
60. Williams CS, Luongo C, Radhika A, Zhang T, Lamps LW, Nanney LB, Beauchamp RD, DuBois RN (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111: 1134-1140
61. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN (2000) Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 105: 1589-1594
62. Wilson CL, Heppner KJ, Labosky PA, Hogan BLM, Matrisian LM (1997) Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci USA 94: 1402-1407